Carisma reports 75% ctDNA reduction in HER2 3+ patients in Phase 1 CT-0508 trial

Carisma Therapeutics Inc.

75% (6/8) evaluable HER2 3+ patients had ctDNA reduction (median 81%, range 33%-93%); no reduction in 5 HER2 2+ patients.
Best overall response: stable disease in 44% (4/9) of HER2 3+ patients; all HER2 2+ patients had progressive disease.
Phase 1 CT-0508 enrollment halted April 2024; all patient activities completed as of July 2024.
Company expects clinical data updates in Q3 2024 and initial Phase 1 data for follow-on CT-0525 in Q4 2024.
Preliminary data supports mechanism of action and potential for repeat dosing with CT-0525 in HER2 overexpressing cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.